Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Good-The Bad and The Ugly -- Ignore unavailable to you. Want to Upgrade?

To: Tim Luke who wrote (4113)	11/15/2000 2:26:20 PM
From: VegasMan	Read Replies (1) \| Respond to of 8686

All: I know i usually don't throw my opinions out to often but I thought this might be interesting to some(i wont lie either...I own the stock) NEW ORLEANS, Nov 15 (Reuters) - Scios Inc.'s drug Natrecor performed better than standard treatment nitroglycerin in relieving symptoms of heart failure, scientists saidWednesday. A clinical trial showed treating chronic heart failure with Natrecor, known generically as nesiritide, improved symptoms such as shortness of breath. Natrecor performed better than a placebo and intravenous nitroglycerin with fewer side effects, said Dr. James Young of the Cleveland Clinic. "It was faster, more effective, better tolerated and easier to use," Young said in a statement. The trial was designed to address concerns of the U.S. Food and Drug Administration (FDA), which last year rejected Scios' application to market Natrecor. Given the new data, "I would be very surprised if the drug does not get final approval soon," Young told reporters at the American Heart Association's annual scientific meeting.